Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo. Try Elite Free for 7 Days
Login Sign up free
Home Screener Maps Charts News Groups Insider Futures Forex Crypto Portfolio Calendar
Pricing
Market News Market Pulse Stocks News ETF News Crypto News

Oculis Holding AG

Contributing Author

Recent Articles by Oculis Holding AG

Aug-24
First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis OCS GlobeNewswire
Aug-24
First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis OCS GlobeNewswire
Aug-14
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities OCS GlobeNewswire
Aug-10
Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis' Position as an Emerging Leading Neuro-Ophthalmology Company OCS GlobeNewswire
Aug-10
Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis' Position as an Emerging Leading Neuro-Ophthalmology Company OCS GlobeNewswire
Aug-06
Oculis Reports Q2 2026 Financial Results and Provides Company Update OCS GlobeNewswire
Aug-06
Oculis Reports Q2 2026 Financial Results and Provides Company Update OCS GlobeNewswire
Aug-06
Oculis Reports Q2 2026 Financial Results and Provides Company Update OCS GlobeNewswire
Aug-06
Oculis Reports Q2 2026 Financial Results and Provides Company Update OCS GlobeNewswire
Aug-03
Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses OCS +5.13% GlobeNewswire
Aug-03
Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses OCS +5.13% GlobeNewswire
Jul-08
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities OCS GlobeNewswire
Jul-02
Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference OCS GlobeNewswire
Jul-02
Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference OCS GlobeNewswire
Jun-15
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities OCS GlobeNewswire
Jun-11
Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026 OCS GlobeNewswire
Jun-11
Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026 OCS GlobeNewswire
Jun-10
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities OCS GlobeNewswire
Jun-09
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities OCS GlobeNewswire
Jun-09
Oculis Announces First Patient Randomized in PREDICT-1 Registrational Trial of Licaminlimab, Advancing Precision Medicine in Dry Eye Disease OCS GlobeNewswire
Jun-09
Oculis Announces First Patient Randomized in PREDICT-1 Registrational Trial of Licaminlimab, Advancing Precision Medicine in Dry Eye Disease OCS GlobeNewswire
Jun-08
Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference OCS GlobeNewswire
Jun-08
Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference OCS GlobeNewswire
May-29
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities OCS -23.42% OCS -36.09% GlobeNewswire
May-29
Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema OCS -23.42% OCS -36.09% GlobeNewswire
May-29
Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema OCS -23.42% OCS -36.09% GlobeNewswire
May-28
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities OCS GlobeNewswire
May-15
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities OCS OCS -7.33% GlobeNewswire
May-14
Oculis Publishes Results of 2026 Annual General Meeting and Announces Election of Gregory D. Perry to its Board of Directors OCS GlobeNewswire
May-14
Oculis Publishes Results of 2026 Annual General Meeting and Announces Election of Gregory D. Perry to its Board of Directors OCS GlobeNewswire
May-11
Oculis Reports Q1 2026 Financial Results and Provides Company Update OCS OCS -6.86% GlobeNewswire
May-11
Oculis Reports Q1 2026 Financial Results and Provides Company Update OCS OCS -6.86% GlobeNewswire
May-07
Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial OCS +5.10% GlobeNewswire
May-07
Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial OCS +5.10% GlobeNewswire
May-05
Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting OCS GlobeNewswire
May-05
Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting OCS GlobeNewswire
May-01
Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting OCS GlobeNewswire
May-01
Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting OCS GlobeNewswire
Apr-21
Oculis Publishes Invitation to the Annual General Meeting OCS GlobeNewswire
Apr-21
Oculis Publishes Invitation to the Annual General Meeting OCS GlobeNewswire
Apr-20
Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema OCS GlobeNewswire
Apr-20
Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema OCS GlobeNewswire
Apr-08
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities OCS GlobeNewswire
Apr-07
Oculis to Participate in Upcoming Investor Conferences OCS GlobeNewswire
Mar-31
Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First-in-Class Neuroprotective Candidate for Optic Neuritis OCS +8.31% GlobeNewswire
Mar-31
Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First-in-Class Neuroprotective Candidate for Optic Neuritis OCS +8.31% GlobeNewswire
Mar-27
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities OCS GlobeNewswire
Mar-16
Oculis to Present at Upcoming North American Neuro-Ophthalmology Society Annual Meeting OCS GlobeNewswire
Mar-16
Oculis to Present at Upcoming North American Neuro-Ophthalmology Society Annual Meeting OCS GlobeNewswire
Mar-16
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities OCS GlobeNewswire
Mar-13
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities OCS -6.15% GlobeNewswire
Mar-11
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities OCS GlobeNewswire
Mar-06
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities OCS GlobeNewswire
Mar-05
Oculis to Participate in Upcoming Investor Conferences OCS GlobeNewswire
Mar-05
Oculis Publishes 2025 Consolidated Financial Statements OCS GlobeNewswire
Mar-05
Oculis to Participate in Upcoming Investor Conferences OCS GlobeNewswire
Mar-04
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities OCS GlobeNewswire
Mar-03
Oculis Reports Q4 and Full Year 2025 Financial Results and Provides Company Update OCS GlobeNewswire
Mar-03
Oculis Reports Q4 and Full Year 2025 Financial Results and Provides Company Update OCS GlobeNewswire
Feb-27
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities OCS GlobeNewswire
Feb-18
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated OCS GlobeNewswire
Feb-17
Oculis Appoints Katie Kazem as Chief Legal Officer OCS GlobeNewswire
Feb-17
Oculis Appoints Katie Kazem as Chief Legal Officer OCS GlobeNewswire
Jan-08
Oculis to Showcase Transformative Late-stage Pipeline in Neuro-ophthalmology and Ophthalmology at the 2026 J.P. Morgan Healthcare Conference OCS +5.05% GlobeNewswire
Jan-08
Oculis to Showcase Transformative Late-stage Pipeline in Neuro-ophthalmology and Ophthalmology at the 2026 J.P. Morgan Healthcare Conference OCS +5.05% GlobeNewswire
Jan-06
Oculis Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic Neuritis OCS +5.82% GlobeNewswire
Jan-06
Oculis Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic Neuritis OCS +5.82% GlobeNewswire
Jan-05
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities OCS GlobeNewswire
Dec-09
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities OCS GlobeNewswire
Dec-03
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities OCS GlobeNewswire
Nov-28
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities OCS GlobeNewswire
Nov-18
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities OCS GlobeNewswire
Nov-10
Oculis Reports Q3 2025 Financial Results and Provides Company Update OCS GlobeNewswire
Nov-10
Oculis Reports Q3 2025 Financial Results and Provides Company Update OCS GlobeNewswire
Nov-05
Oculis to Participate in Upcoming November Investor Conferences OCS GlobeNewswire
Nov-05
Oculis to Participate in Upcoming November Investor Conferences OCS GlobeNewswire
Oct-30
Oculis Announces Oversubscribed $110 Million Financing to Accelerate Privosegtor Development OCS -6.77% GlobeNewswire
Oct-30
Oculis Announces Oversubscribed $110 Million Financing to Accelerate Privosegtor Development OCS -6.77% GlobeNewswire
Oct-14
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities OCS GlobeNewswire
Oct-14
Oculis to Spotlight Transformative Late-Stage Pipeline at Eyecelerator and AAO 2025 OCS GlobeNewswire
Oct-14
Oculis to Spotlight Transformative Late-Stage Pipeline at Eyecelerator and AAO 2025 OCS GlobeNewswire
Oct-08
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities OCS OCS +6.34% GlobeNewswire
Oct-06
Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-class Neuroprotective Therapy OCS +5.61% GlobeNewswire
Oct-06
Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-class Neuroprotective Therapy OCS +5.61% GlobeNewswire
Sep-26
Oculis Publishes Notification of Transactions by Person Discharging Managerial Responsibilities OCS GlobeNewswire
Sep-22
Oculis Announces Presentation of Phase 2 ACUITY trial results with Privosegtor in Acute Optic Neuritis at ECTRIMS OCS +6.68% GlobeNewswire
Sep-22
Oculis Announces Presentation of Phase 2 ACUITY trial results with Privosegtor in Acute Optic Neuritis at ECTRIMS OCS +6.68% GlobeNewswire
Sep-09
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities OCS GlobeNewswire
Sep-04
Oculis and EURETINA Announce the Winner of the Ramin Tadayoni Award 2025 OCS GlobeNewswire
Sep-04
Oculis and EURETINA Announce the Winner of the Ramin Tadayoni Award 2025 OCS GlobeNewswire
Sep-03
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities OCS GlobeNewswire
Sep-01
Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology Conferences OCS GlobeNewswire
Sep-01
Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology Conferences OCS GlobeNewswire
Aug-28
Oculis to Participate in Upcoming September Investor Conferences OCS -5.63% GlobeNewswire
Aug-28
Oculis to Participate in Upcoming September Investor Conferences OCS -5.63% GlobeNewswire
Aug-25
Oculis Appoints Mark Kupersmith, M.D., and Sebastian Wolf, M.D., Ph.D., World-Renowned Neuro-Ophthalmology and Retina Experts, as Chief Medical Advisors OCS GlobeNewswire
Aug-25
Oculis Appoints Mark Kupersmith, M.D., and Sebastian Wolf, M.D., Ph.D., World-Renowned Neuro-Ophthalmology and Retina Experts, as Chief Medical Advisors OCS GlobeNewswire
Aug-21
Oculis Reports Q2 2025 Financial Results and Provides Company Update OCS GlobeNewswire
Aug-21
Oculis Reports Q2 2025 Financial Results and Provides Company Update OCS GlobeNewswire
Aug-12
Oculis to Participate in Upcoming H.C Wainwright 5th Annual Ophthalmology Virtual Conference OCS GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)